IMMUNITYBIO, INC. Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment
IMMUNITYBIO, INC. (IBRX) reported Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment of $27.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment · last filed 2026-02-23
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2025-12-31 was $23.90M, a 1857.58% increase year-over-year.
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2025-09-30 was -$7.55M.
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2025-06-30 was -$7.54M.
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for the quarter ending 2025-03-31 was $18.74M.
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2025 was $27.56M, a 2156.92% increase from fiscal 2024.
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2024 was $1.22M.
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2023 was $0.00.
- IMMUNITYBIO, INC. other comprehensive income (loss), financial liability, fair value option, after tax and reclassification adjustment for fiscal 2022 was $0.00.
| Period end | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 3 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 6 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 9 month | Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment 12 month |
|---|---|---|---|---|
| 2025-12-31 | $23.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $16.35M derived: sum of 2 quarters · filed 2026-02-23 | $8.81M derived: sum of 3 quarters · filed 2026-02-23 | $27.56M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$7.55M 10-Q · filed 2025-11-05 | -$15.09M derived: sum of 2 quarters · filed 2025-11-05 | $3.65M 10-Q · filed 2025-11-05 | $4.88M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-06-30 | -$7.54M 10-Q · filed 2025-08-05 | $11.21M 10-Q · filed 2025-08-05 | $12.43M derived: sum of 3 quarters · filed 2026-02-23 | $12.43M derived: sum of 4 quarters · filed 2026-02-23 |
| 2025-03-31 | $18.74M 10-Q · filed 2025-05-12 | $19.96M derived: sum of 2 quarters · filed 2026-02-23 | $19.96M derived: sum of 3 quarters · filed 2026-02-23 | $19.96M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-12-31 | $1.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $1.22M derived: sum of 2 quarters · filed 2026-02-23 | $1.22M derived: sum of 3 quarters · filed 2026-02-23 | $1.22M 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | -$820.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-05 | $0.00 10-Q · filed 2025-08-05 | -$820.00K derived: sum of 3 quarters · filed 2026-02-23 | $0.00 derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-12 | -$820.00K derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | |
| 2023-12-31 | -$820.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 | |
| 2023-09-30 | $820.00K 10-Q · filed 2024-11-12 | $820.00K 10-Q · filed 2024-11-12 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | |
| 2022-09-30 | $0.00 10-Q · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |